18 pharma companies lose licence for manufacturing spurious drugs
Mar 29, 2023, at 06:22 am
New Delhi: The government has cancelled the licences of 18 pharma companies for producing spurious and adulterated drugs, following joint inspections by central and state regulators at 76 drug manufacturers, a media report said.
Dr Rajeev Raghuvanshi appointed as the new Drug Controller General of India
Feb 23, 2023, at 03:17 am
New Delhi/IBNS: The Appointments Committee of the Cabinet on Wednesday approved the appointment of Dr Rajeev Raghuvanshi as the new Drug Controller General of India (DCGI) was approved by the, an official release stated.
Covishield and Covaxin get DCGI's conditional approval for sale in regular market
Jan 27, 2022, at 10:22 pm
New Delhi/IBNS: Covishield and Covaxin have been granted approval by drugs regulator Drugs Control Regulator General of India (DCGI) for sale in the regular market.
Anti-COVID-19 pill Molnupiravir cleared by DCGI has safety concerns: ICMR chief
Jan 07, 2022, at 04:36 pm
New Delhi/IBNS: Indian Council of Medical Research (ICMR) chief Balram Bhargava on Wednesday said anti-COVID-19 pill Molnupiravir, which has been cleared by India's drug regulator, has "major safety concerns".
Bharat Biotech's Covaxin recommended for use in children below 18 years
Oct 13, 2021, at 03:23 am
New Delhi/IBNS: An expert panel on Tuesday recommended Bharat Biotech's Covaxin to be administered on children between the ages of two and 18.
Zydus Cadila receives emergency approval for use on children above 12 years
Aug 21, 2021, at 04:29 am
New Delhi/IBNS: Zydus Cadila has received approval for Emergency Use Authorization (EUA) of its COVID-19 vaccine, ZyCoV-D, from the Drug Controller General of India (DCGI) to be administered on children and adults 12 years and above.
DCGI approves DRDO's anti-COVID oral drug '2-DG' for emergency use
May 08, 2021, at 11:57 pm
New Delhi/IBNS: The Drug Controller General of India (DCGI) has approved the emergency use of DRDO's anti-COVID-19 therapeutic oral drug 2-deoxy-D-glucose (2-DG) as an adjunct therapy in moderation to severe COVID-19 patients.
Covaxin taken off clinical trial mode, no consent forms required
Mar 12, 2021, at 03:38 am
New Delhi/IBNS: Pharmaceutical company Bharat Biotech's indigenous Coronavirus vaccine-Covaxin-has been taken off the clinical trial mode, which means beneficiaries will not have to sign consent forms before taking the drug.
Serum Institute, Bharat Biotech get DCGI approval for emergency use of Covid-19 vaccines
Jan 03, 2021, at 05:58 pm
New Delhi/IBNS: Two Covid-19 vaccine candidates-Hyderabad-based Bharat Biotech's Covaxin and the Serum Institute of India's Covishield-on Sunday received the approval of the Drugs Controller General of India (DCGI) for emergency use in India.
Two Covid-19 vaccine candidates await DCGI approval for emergency use in India
Jan 03, 2021, at 04:24 pm
New Delhi/IBNS: Two Covid-19 vaccine candidates in India-Hyderabad-based Bharat Biotech's Covaxin and the Serum Institute of India's Covishield-now awaits the approval of the Drugs Controller General of India (DCGI) for emergency use after they have been cleared by the government-appointed panel.
Covid vaccine approval likely soon : DCGI
Dec 31, 2020, at 11:29 pm
New Delhi/IBNS: The coronavirus vaccines awaiting approval can be cleared soon, India's drug control authority said Thursday.
Serum Institute gets DCGI nod to resume Covid-19 vaccine
Sep 16, 2020, at 04:25 pm
New Delhi/IBNS: The Serum Institute of India (SII) has got the nod of the Drug Controller General of India (DCGI) to resume the phase two and three trials for Covid-19 vaccine, media reports said.
After Oxford Covid-19 Vaccine trial pause, DCGI sends show-cause notice to Serum Institute
Sep 10, 2020, at 04:23 am
New Delhi/IBNS: After pharmaceutical giant AstraZeneca halted the Phase 3 study testing of the Oxford Vaccine against Covid-19, the Drugs Controller General of India (DCGI) on Wednesday issued a show-cause notice to Serum Institute of India (SII) for not informing the central drug regulator about the pause of trials in other countries.
'Process as per global norms': ICMR defends Aug 15 deadline for COVAXIN
Jul 04, 2020, at 11:27 pm
New Delhi/IBNS: The Indian Council of Medical Research (ICMR) has defended the August 15 launch of COVAXIN, after the scientific community of the country termed the short timeline "risky" and "impossible", a media report said.
India's first COVID-19 vaccine gets DCGI's approval for human trials: Report
Jun 30, 2020, at 01:31 am
Hyderabad/IBNS: India's first homegrown Covid-19 vaccine candidate COVAXIN has received approval from Drug Controller General of India (DCGI) to conduct Phase I and II human trials, said a media report.